Celularity Announces Chief Financial Officer Transition
FLORHAM PARK, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ('Celularity' or the 'Company'), a regenerative and cellular medicine company, today announced that it terminated the employment of its Chief Financial Officer ('CFO'), David Beers, effective immediately. Mr. Beer's termination was not related to the Company's financial or operating results or to any disagreements or concerns regarding the Company's financial or reporting practices. Mr. Beers was terminated 'without cause' under the terms of his employment agreement dated April 1, 2022, as amended and restated, and, subject to his compliance with its terms, Mr. Beers will be entitled to the payments and benefits provided therein following a termination without cause.
Effective as of June 10, 2025, the Company appointed Joseph DosSantos, its current Senior Vice President Finance, as the Company's interim CFO while the Company conducts a search for a new CFO. Mr. DosSantos will continue to serve as the Company's Senior Vice President Finance during his time as interim CFO and will not receive any additional compensation in connection with his role as interim CFO.
The Company also announced that it retained the CFO Squad, a leading financial and business advisory firm providing outsourced accounting and consulting services for emerging to mid-sized companies, to provide support during this interim period, including SEC and financial reporting support services and consulting services to identify opportunities to improve and optimize the Company's financial processes and systems. The CFO Squad will work under the direction of John R. Haines, Celularity's Senior Executive Vice President and Chief Administrative Officer.
About Celularity
Celularity Inc. (Nasdaq: CELU) is a regenerative and cellular medicine company developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Celularity believes that by harnessing the placenta's unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies. For more information about Celularity and its cutting-edge regenerative medicine solutions, please visit www.celularity.com.
Contact
Carlos RamirezSenior Vice President, Celularity Inc.Carlos.ramirez@celularity.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
35 minutes ago
- Business Insider
NVDA vs. BBAI vs. SOUN: Which AI Stock Is the Best Pick, According to Analysts?
Wall Street is bullish on the prospects of several artificial intelligence (AI) stocks as spending remains resilient despite macro uncertainties. The use of generative AI to automate tasks and enhance productivity is increasing rapidly, presenting massive growth opportunities for companies in the AI space. Using TipRanks' Stock Comparison Tool, we placed Nvidia (NVDA), Holdings (BBAI), and SoundHound AI (SOUN) against each other to find the best AI stock, according to Wall Street analysts. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Nvidia (NASDAQ:NVDA) Stock Nvidia stock has risen about 19% year-to-date, marking a rebound from the weakness seen earlier this year due to tariff pressures, macro uncertainty, growing competition, and chip export restrictions. The company reported market-beating results for the first quarter of Fiscal 2025, reflecting robust demand for its GPUs (graphics processing units), which are essential for building and training AI models. Looking ahead, Nvidia is confident about capturing elevated demand for its AI chips, supported by innovative offerings like the Blackwell platform. Moreover, the company is well-positioned to capture growth opportunities in sovereign AI and robotics. Is Nvidia Stock a Buy? Recently, Mizuho analyst Vijay Rakesh increased the price target for Nvidia stock to $185 from $170 and maintained a Buy rating. The 5-star analyst's revised price forecast for NVDA stock reflects an increase in his Fiscal 2026 revenue and EPS (earnings per share) estimates from $195 billion and $4.16 to $202 billion and $4.38, respectively. Rakesh also increased his top and bottom-line estimates for Fiscal 2027 and Fiscal 2028, citing slightly improved GPU supply and pulled-in demand for GB300 and air-cooled Rubin platform as key drivers. While Rakesh increased his Fiscal 2025 estimates, he maintained his revenue and EPS forecast for Q2 FY25 at $45 billion and $0.98, respectively, with data center revenue expected to rise 5% quarter-over-quarter to $41 billion. He expects strong demand for GB200 chips in the second half of 2025, ahead of the GB300 ramp, which could potentially more than offset the loss of revenue from H20 chips. Overall, Wall Street has a Strong Buy consensus rating on Nvidia stock, backed by 35 Buys, four Holds, and one Sell recommendation. At $175.69, the average Nvidia stock price target indicates 10.3% upside potential. Holdings (NYSE:BBAI) Stock stock has rallied by an impressive 74.2% year-to-date and 424% over the past year, as investors are optimistic about the growth potential of the company's AI-powered decision intelligence solutions. The Russell 2000 AI stock has been gaining the attention of small-cap investors. While 5% revenue growth in Q1 2025 was not impressive, BBAI bulls are optimistic about better days ahead, driven by a strong backlog of $385 million and recent contract wins. For instance, last month, the company announced a strategic partnership with Easy Lease and Vigilix Technology to accelerate AI in the United Arab Emirates (UAE). Is BBAI Stock a Good Buy? Earlier this month, H.C. Wainwright analyst Scott Buck increased the price target for stock to $9 from $6 and reaffirmed a Buy rating. The analyst noted the outperformance of BBAI stock compared to the Russell 2000 Index in the first half of the year, driven by new customers and contracts as well as underlying secular trends in the AI-driven defense and security space. Buck highlighted the double-digit revenue growth expectations for 2026, bolstered by a strong backlog and favorable signs indicating that BBAI's products are gaining traction in key growth verticals like border security, defense, intelligence, and critical infrastructure. Consequently, Buck sees the possibility of multiple expansion for BBAI stock ahead of the expected improvement in the financial results in the second half of 2025 and 2026. Currently, Wall Street is divided on BBAI stock, with a Moderate Buy consensus rating based on two Buys and two Hold recommendations. The average stock price target of $5.83 indicates about 25% possible downside from current levels. SoundHound AI (NASDAQ:SOUN) Stock SoundHound AI offers artificial intelligence-powered voice and conversational intelligence solutions to several end markets, including retail, automotive, healthcare, and restaurants. After rallying more than 800% in 2024, SOUN stock is down 44% year-to-date. The company delivered a 151% growth in its Q1 2025 revenue. Moreover, it ended the quarter with cash and cash equivalents of $246 million and no debt. However, profitability concerns, rising competition in the voice AI space, SoundHound stock's lofty valuation, and Nvidia's sale of its stake in the company have adversely impacted investor sentiment. Is SoundHound Stock a Good Buy? In a research note last month, Northland Securities analyst Michael Latimore highlighted SoundHound's position as a pioneer in speech recognition and language understanding. The 4-star analyst also highlighted the gains from the Amelia acquisition and the strength of the proprietary SoundHound Voice AI platform, which offers robust speed and accuracy in understanding complex voice queries. Latimore noted Agentic AI opportunities and management's expectation of material acceleration in the second half of 2025. That said, Latimore currently has a Hold rating on SOUN stock with a price target of $8, which indicates a 28% downside risk. While the prospects of SoundHound AI look bright, considering a total addressable market (TAM) of $140 billion across multiple industries, analysts are divided on the stock due to its steep valuation and other concerns. With four Buys and three Holds, Wall Street has a Moderate Buy consensus rating on SoundHound AI stock. The average SOUN stock price forecast of $11.50 indicates a modest upside of 3.7%. Conclusion Wall Street is cautiously optimistic about Holdings and SoundHound AI stocks, but highly bullish on Nvidia stock as a top AI play. Analysts see higher upside potential in NVDA stock than in the other two AI stocks from current levels. Nvidia's dominant position in the AI GPU space, solid fundamentals, and relentless innovation support analysts' bullish stance.
Business Wire
4 hours ago
- Business Wire
HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Harrow, Inc. ('Harrow' or 'the Company') (NASDAQ: HROW) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Harrow announced its financial results for Q1 2025 on May 8, 2025. The Company reported revenues that missed consensus estimates and adjusted EBITDA of -$1.9 million. Based on this news, shares of Harrow fell by more than 4%. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Associated Press
4 hours ago
- Associated Press
Kessler Topaz Meltzer & Check, LLP Reminds MSTR Shareholders of Deadline in Securities Fraud Class Action Lawsuit Filed Against MicroStrategy Incorporated d/b/a Strategy (MSTR)
RADNOR, PA - July 6, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( ) informs investors that a securities class action lawsuit has been filed against MicroStrategy Incorporated d/b/a Strategy ('Strategy') ( NASDAQ: MSTR ) on behalf of those who purchased or otherwise acquired Strategy securities between April 30, 2024, and April 4, 2025, inclusive (the 'Class Period'). The lead plaintiff deadline is July 15, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Strategy losses, you may CLICK HERE or copy and paste the following link into your browser: You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding Strategy's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the anticipated profitability of Strategy's bitcoin-focused investment strategy and treasury operations was overstated; (2) the various risks associated with bitcoin's volatility and the magnitude of losses Strategy could recognize on the value of its digital assets following its adoption of ASU 2023-08 were understated; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times. THE LEAD PLAINTIFF PROCESS: Strategy investors may, no later than July 15, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages Strategy investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit CONTACT: Kessler Topaz Meltzer & Check, LLP Jonathan Naji, Esq. (484) 270-1453 280 King of Prussia Road Radnor, PA 19087 [email protected] May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. View the original release on
